Back to results
US 2019/0335726 A1Published application
Genetically modified cells, tissues, and organs for treating disease
AssigneeRegents of the University of Minnesota
InventorsBernhard J. Hering, Christopher Burlak
Life of this patent
Estimating the term…
Abstract
Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.
Claims29
-147. (canceled)
A genetically modified non-human animal comprising an exogenous nucleic acid sequence at least 95% identical to SEQ ID NO:
- 359 or SEQ ID NO:
- 502.
(canceled)
A genetically modified non-human cell, tissue, or organ comprising an exogenous nucleic acid sequence at least 95% identical to SEQ ID NO:
- 359 or SEQ ID NO:
- 502.
A method of making a genetically modified pig comprising:
- a) obtaining a porcine fetal fibroblast cell comprising—an exogenous nucleic acid sequence at least 95% identical to SEQ ID NO:
- 359 or SEQ ID NO:
- 502;
- b) genetically modifying said porcine fetal fibroblast cell using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas by (i) disrupting a gene encoding a glycoprotein galactosyltransferase alpha 1,3 (GGTA1) in the porcine fetal fibroblast cell comprising the exogenous nucleic acid sequence, or (ii) inserting the exogenous nucleic acid sequence at least 95% identical to SEQ ID NO:
- 359 or SEQ ID NO:
- 502 in the porcine fetal fibroblast cell comprising the disrupted gene encoding the GGTA1;
- c) transferring a nucleus of the genetically modified porcine fetal fibroblast cell to a porcine enucleated oocyte to generate an embryo;
- and
- d) transferring the embryo into a surrogate pig and growing the transferred embryo to the genetically modified pig in the surrogate pig.
6 more elements
Dependencies are inferred from the claim text.